BioCapTM ASCL1 mRNA
Catalog Number: 1003501| SKU | Price | Buy |
|---|---|---|
| 1003501-500ug | $1,550.00 | |
| 1003501-1mg | $2,025.00 |
Description
ASCL1 / ASH1 BHLHA46 HASH1
SPECIES:
Human
ENCODED PROTEIN NAME:
Achaete-scute homolog 1
Function:
Transcription factor that plays a key role in neuronal differentiation: acts as a pioneer transcription factor, accessing closed chromatin to allow other factors to bind and activate neural pathways. Directly binds the E box motif (5'-CANNTG-3') on promoters and promotes transcription of neuronal genes. The combination of three transcription factors, ASCL1, POU3F2/BRN2 and MYT1L, is sufficient to reprogram fibroblasts and other somatic cells into induced neuronal (iN) cells in vitro. Plays a role at early stages of development of specific neural lineages in most regions of the CNS, and of several lineages in the PNS. Essential for the generation of olfactory and autonomic neurons. Acts synergistically with FOXN4 to specify the identity of V2b neurons rather than V2a from bipotential p2 progenitors during spinal cord neurogenesis, probably through DLL4-NOTCH signaling activation. (Source: UniProt http://www.uniprot.org/uniprot/p50553)
Sequence (236 aa):
For the DNA coding sequence that is used as the template to synthesize the ASCL1 mRNA mimetic, please contact us at customerservice@pharna.com.
For potential mRNA mimetics encoding splice variants or isoforms of your interest, please contact us at customerservice@pharna.com and it is our promise to fulfill your needs.
PhaRNA, LLC is looking for academic and industry collaborators and partners to co-develop RNA-based therapeutics including vaccines for the prevention or treatment of microbial diseases caused by parasites, fungi, viruses and bacteria. Our company’s proprietary technology has the versatility of rapidly designing RNA-based products for testing and development in preclinical and clinical settings. More specifically, we are looking for potential collaborators and partners who have the capacity to take our custom-designed RNA products and test their efficacy using molecular, cell biological and animal models. We will then partner to develop the most promising drug candidates through early phase clinical studies. We believe that this form of collaboration will capitalize on the strengths of PhaRNA, LLC and the partnering organization to rapidly test and develop potentially life-saving drugs and vaccines. Interested parties, please contact us directly.